ApprovalTrail

Approval · Notice of Compliance 423 · 2003

CLOZARIL: Notice of Compliance 423

Issued February 20, 2003

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
423
Date
February 20, 2003
Company
Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Revised product monograph
Therapeutic class
Antipsychotic agent

Products in this notice

BrandDINStatus today
CLOZARILNot yet assigned—

Medicinal ingredients